Safety, tolerability, and pharmacokinetics of a novel anti-influenza agent ZX-7101A tablets in healthy chinese participants: A first-in-human phase I clinical study

• Published in: International journal of antimicrobial agents Vol. 65; no. 1; p. 107381
• Main Authors: Wu, Junzhen, Wei, Qiong, Jin, Yi, Cao, Guoying, Yu, Jicheng, Wu, Xiaojie, Yang, Xinyi, Li, Yilin, Liu, Mei, Qin, Xiaoli, Ai, Jingwen, Wang, Yin, Zhang, Wenhong, Zhang, Jing
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.01.2025
• Subjects: Cap-dependent endonuclease inhibitor; Infectious Disease; Influenza; Pharmacokinetics; Safety; ZX-7101; ZX-7101A tablets; Cap-dependent endonuclease inhibitor; ZX-7101A tablets; Safety; Pharmacokinetics; ZX-7101; Influenza

•ZX-7101A is a novel cap-dependent endonuclease inhibitor.•A single dose of 40–320 mg ZX-7101A was safe and well-tolerated in healthy subjects.•A single oral dose of 40 mg and 80 mg was expected to exhibit adequate in vivo anti-influenza activity.•A high-fat meal decreased the exposure level of ZX-7...